GAMMA Investing LLC Buys 5,928 Shares of Immunome, Inc. (NASDAQ:IMNM)

GAMMA Investing LLC increased its stake in Immunome, Inc. (NASDAQ:IMNM) by 2,822.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,138 shares of the company’s stock after acquiring an additional 5,928 shares during the quarter. GAMMA Investing LLC’s holdings in Immunome were worth $410,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of IMNM. Wellington Management Group LLP increased its stake in Immunome by 3.5% during the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock valued at $1,546,000 after purchasing an additional 4,874 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Immunome by 5.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock worth $441,000 after acquiring an additional 2,005 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Immunome by 32.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,193 shares of the company’s stock worth $618,000 after acquiring an additional 14,328 shares during the last quarter. Woodline Partners LP boosted its holdings in shares of Immunome by 6.1% in the 4th quarter. Woodline Partners LP now owns 980,925 shares of the company’s stock worth $10,417,000 after buying an additional 56,533 shares during the last quarter. Finally, Two Sigma Advisers LP purchased a new position in shares of Immunome in the 4th quarter worth about $512,000. Institutional investors own 44.58% of the company’s stock.

Immunome Trading Down 1.3%

IMNM stock opened at $8.83 on Friday. The company’s 50 day moving average is $8.45 and its 200 day moving average is $9.35. The stock has a market cap of $768.30 million, a price-to-earnings ratio of -2.78 and a beta of 1.94. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $16.81.

Immunome (NASDAQ:IMNM) last issued its earnings results on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.14. The business had revenue of $2.93 million during the quarter, compared to analyst estimates of $0.46 million. Immunome had a negative return on equity of 71.65% and a negative net margin of 1,875.21%. As a group, sell-side analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Wall Street Zen raised shares of Immunome from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Lake Street Capital assumed coverage on Immunome in a research note on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 price objective on the stock. Lifesci Capital began coverage on Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $21.00 price target (down from $33.00) on shares of Immunome in a research report on Tuesday, May 13th. Finally, Guggenheim decreased their price target on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Immunome presently has an average rating of “Moderate Buy” and an average target price of $23.33.

Insiders Place Their Bets

In other Immunome news, Director Jean Jacques Bienaime purchased 7,000 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The stock was bought at an average price of $8.21 per share, with a total value of $57,470.00. Following the completion of the purchase, the director now directly owns 23,615 shares of the company’s stock, valued at $193,879.15. The trade was a 42.13% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CTO Philip Tsai purchased 12,300 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The stock was acquired at an average cost of $8.42 per share, with a total value of $103,566.00. Following the purchase, the chief technology officer now directly owns 33,300 shares of the company’s stock, valued at $280,386. This trade represents a 58.57% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 161,400 shares of company stock valued at $1,207,395 over the last quarter. 8.60% of the stock is owned by corporate insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.